ResMed Inc. (FRA:RME)
Germany · Delayed Price · Currency is EUR | Market Cap | 22.77B -30.1% |
| Revenue (ttm) | 4.80B +10.3% |
| Net Income | 1.32B +15.7% |
| EPS | 8.99 +16.4% |
| Shares Out | n/a |
| PE Ratio | 17.28 |
| Forward PE | 15.33 |
| Dividend | 2.05 (1.29%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | n/a |
| Open | 155.70 |
| Previous Close | 156.50 |
| Day's Range | 155.70 - 163.00 |
| 52-Week Range | 155.70 - 250.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]
Financial Performance
In fiscal year 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.
Financial numbers in USD Financial StatementsNews
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
Angelini Ventures marks its first portfolio exit as ResMed acquires Noctrix Health, validating its strategy of backing breakthrough healthcare innovation.
ResMed Transcript: 46th Annual William Blair Growth Stock Conference
Operating in a vast, under-penetrated market, the company leverages innovation, strategic acquisitions, and digital health partnerships to drive growth and patient engagement. Strong financial performance supports increased R&D, share buybacks, and expansion into new therapy areas like Restless Legs Syndrome.
ResMed Slides: 46th Annual William Blair Growth Stock Conference
ResMed has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). Acquisition a...
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the...
ResMed, Oura partner to expand access to sleep health education
Resmed (RMD) and Oura announced they are partnering to expand access to sleep health education and pathways to care. By connecting consumer-generated wellness insights with Resmed’s sleep health resou...
Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world...
ResMed price target lowered to $225 from $254 at Baird
Baird lowered the firm’s price target on ResMed (RMD) to $225 from $254 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results and…
ResMed price target lowered to $235 from $265 at Stifel
Stifel lowered the firm’s price target on ResMed (RMD) to $235 from $265 and keeps a Hold rating on the shares.
ResMed beats quarterly profit estimates, names new CFO
Medical device maker ResMed beat third‑quarter profit estimates on Thursday, driven by strong demand for its medical devices, while appointing Aaron Bloomer as its new chief financial officer.
ResMed CFO Brett Sandercock to retire, Aaron Bloomer to succeed
Resmed (RMD) announced that Brett Sandercock, CFO, plans to retire effective May 4. After conducting a search, Aaron Bloomer has been appointed as his successor. Bloomer joinsResmedfrom Exact Sciences...
ResMed Earnings Call Transcript: Q3 2026
Q3 FY26 saw 11% revenue growth, 21% non-GAAP EPS growth, and strong margin expansion. Announced Noctrix Health acquisition and CFO transition, with robust cash flow and continued investment in innovation and shareholder returns.
ResMed Earnings release: Q3 2026
ResMed released its Q3 2026 earnings on April 30, 2026, summarizing the period's financial results.
ResMed Slides: Q3 2026
ResMed has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 30, 2026.
ResMed Quarterly report: Q3 2026
ResMed has published its Q3 2026 quarterly earnings report on April 30, 2026.
ResMed reports Q3 EPS $2.86, consensus $2.72
Reports Q3 revenue $1.43B, consensus $1.42B. “Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined ...
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett...
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% GAAP income from operations increased 17%...
ResMed price target lowered to $290 from $302 at KeyBanc
KeyBanc lowered the firm’s price target on ResMed (RMD) to $290 from $302 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The firm believes underlying…
ResMed initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of ResMed (RMD) with an Overweight rating and A$37.60 price target The firm says ResMed is the global leader in the obstructive sleep apnea market. While therapeutics,…
ResMed price target lowered to $255 from $300 at Evercore ISI
Evercore ISI analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $255 from $300 and keeps an Outperform rating on the shares. The firm adjusted estimates and…
ResMed price target lowered to $340 from $345 at Citi
Citi lowered the firm’s price target on ResMed (RMD) to $340 from $345 and keeps a Buy rating on the shares.
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, ...
Resmed's Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains 53% of people surveyed rank sleep as the most important behavior for a long, h...
ResMed At $250: Missed Opportunity Or A Trap In The Making?
ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maint...